Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652574 · ClinicalTrials.gov registry record · Phase 1
Dasatinib in Resectable Malignant Pleural Mesothelioma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00652574: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00652574 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652574, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how dasatinib affects biomarker levels in patients with malignant pleural mesothelioma that may be able to be removed by surgery. The safety and effectiveness of this drug will also be studied. This research study is financially supported by the United States Department of Defense.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-03-12 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00652574
The ClinicalTrials.gov registry entry for NCT00652574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00652574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00652574 about?
NCT00652574 is a clinical study titled "Dasatinib in Resectable Malignant Pleural Mesothelioma". The goal of this clinical research study is to learn how dasatinib affects biomarker levels in patients with malignant pleural mesothelioma that may be able to be removed by surgery. The safety and effectiveness of this drug will also be studied. This research study is financially supported by the ...
What is the current status of trial NCT00652574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2008-03-12. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT00652574?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00652574?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.